121 results
Page 4 of 7
424B5
c2m fdy0hv
11 Sep 20
Prospectus supplement for primary offering
4:44pm
8-K
EX-99.2
30arpvr3qrk7 2m0l
9 Sep 20
Intra-Cellular Therapies Announces Proposed Public Offering of Common Stock
5:26pm
8-K
EX-99.1
h5cn glodqg
9 Sep 20
Intra-Cellular Therapies Announces Proposed Public Offering of Common Stock
5:26pm
424B5
0iabdx nl
9 Sep 20
Prospectus supplement for primary offering
4:40pm
8-K
EX-99.1
98gzqax7kfl
9 Sep 20
Intra-Cellular Therapies Announces Positive Topline Results
7:13am
8-K
EX-99.1
zvp l5untmbfly9sq
10 Aug 20
Intra-cellular Therapies Reports Second Quarter 2020 Financial Results and Provides Corporate Update
7:52am
8-K
EX-99.1
24rit z5ak
29 Jun 20
Intra-Cellular Therapies Announces PositiveTop-line Results fromITI-214 Phase I/II Study in Patients with Heart Failure
9:14am
DEFA14A
l7xln
13 May 20
Additional proxy soliciting materials
4:31pm
8-K
EX-99.1
82iuy9 rvh6
7 May 20
Intra-cellular Therapies Reports First Quarter 2020 Financial Results and Provides Corporate Update
7:42am
8-K
EX-99.1
w4clctaba8gb33hv
23 Mar 20
Intra-Cellular Therapies Announces Availability of CAPLYTA™ (lumateperone) for Adult Patients with Schizophrenia
7:52am
8-K
EX-99.1
3emf5n
2 Mar 20
Intra-cellular Therapies Reports Fourth Quarter and Full-year 2019 Financial Results and Provides Corporate Update
7:43am
8-K
EX-99.2
vsbloq0
8 Jan 20
Entry into a Material Definitive Agreement
5:12pm
424B5
05n sby193m
8 Jan 20
Prospectus supplement for primary offering
5:06pm
8-K
EX-99.2
txjd 3nr6rkrcvzph6sa
6 Jan 20
Intra-Cellular Therapies Announces Proposed Public Offering of Common Stock
4:52pm
8-K
EX-99.1
91e4m7tepvdp9n1
6 Jan 20
Intra-Cellular Therapies Announces Proposed Public Offering of Common Stock
4:52pm
424B5
rp0sg96ym8apzkaebt
6 Jan 20
Prospectus supplement for primary offering
4:42pm